Related Experiment Video

Updated: Apr 28, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K

Meeting the current and future challenges of oncology drug development

Moira Howie1, Kathy Oliver2, Angela Timoney3

  • 1Eli Lilly and Company, Lilly UK, Surrey, UK.

Ecancermedicalscience
|June 3, 2014
PubMed

Insights

Understanding patient perspectives on targeted therapy is crucial for health technology assessment (HTA). This session explored challenges and diverse viewpoints on HTA evaluations for cancer treatments.

Area of Science:

  • Oncology
  • Health Economics
  • Health Policy

Background:

  • Targeted therapy represents a significant advancement in cancer treatment.
  • Health Technology Assessment (HTA) is critical for evaluating new therapies.
  • Diverse stakeholder perspectives influence HTA outcomes.

Purpose of the Study:

  • To explore the future and challenges of targeted therapy within HTA.
  • To examine the HTA evaluation process from multiple stakeholder viewpoints.
  • To understand public, patient, and caregiver attitudes towards cancer therapies.

Main Methods:

  • A breakout session featuring leaders from patient advocacy, industry, appraisal committees, and physicians.
  • Presentation of a "Six Nation Public Opinion Survey of Cancer Knowledge and Attitudes".
  • An interactive 'perspectives activity' simulating the HTA process from different roles.

Main Results:

  • Highlighted distinct interpretations of the HTA process by key stakeholders.
  • Provided insights into public and patient perceptions of cancer and its therapies.
  • Facilitated discussion on the complexities and challenges within HTA.

Conclusions:

  • Emphasized the importance of considering multiple perspectives in HTA for targeted therapies.
  • Underscored the need for better understanding of patient and public views in cancer treatment evaluation.
  • Identified key challenges in the HTA process that require collaborative solutions.

More Related Videos

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells10:03

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells

Published on: July 5, 2019

7.9K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

12.8K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.6K